The GHRP-2 Ledger: Who Gets Paid, and What You're Actually Buying

Here’s the number that gets people typing their card details into a research-chemical checkout page. A vial off one of these sites runs 20 to 50 dollars. A month of the same compound, prescribed and compounded through a licensed provider, runs 100 to 250 dollars. Case closed, right? Buy the cheap one.

I don’t trust numbers until I know where they come from. So I did what I always do. I followed the money down the chain, from the vial back to whoever actually touched it, and asked who got paid for what. That’s the only way to know if a price is a bargain or a warning label.

GHRP-2, chemical name pralmorelin, is a six-amino-acid peptide from the early 1990s. It tells your pituitary to fire off a pulse of growth hormone. It sits in the same family as GHRP-6, ipamorelin, and the oral drug MK-677. The human data on it is real, but it’s old, it’s thin, and the compound is banned in tested sport. Keep those three facts in your coat pocket. Everything below leans on them.

This isn’t a pitch. Nobody’s selling anything here. It’s an accounting of who’s telling the truth about what you’re buying.

The ledger has seven line items

I built a scorecard. Seven criteria, weighted by how much each one can hurt you if it’s missing, not by how much it costs. Price shows up, but it doesn’t run the table, because on a lightly studied injectable, one bad batch costs you more than the sticker ever saved.

Medical oversight, 25 points. Does a licensed clinician actually look at your case before anything ships?
Pharmacy licensure, 20 points. Compounded by a state-licensed 503A pharmacy, or shipped “for research only” by an outfit that’s never held a pharmacy license in its life?
Batch testing, 15 points. Is there an independent certificate of analysis tied to your specific lot?
Regulatory honesty, 15 points. Does the seller tell you the truth about what the evidence shows and what the law says?
Aftercare, 10 points. If something goes sideways, is there a person to call?
Real total cost, 10 points. Not the sticker. The all-in cost of getting a known-quality product into your body.
Deal transparency, 5 points. Do you know exactly what you’re paying for before the money moves?

Add up lines 6 and 7. Fifteen points, out of a hundred. That’s deliberate. If price is running your decision on a compound this thinly studied, you’re optimizing for the wrong column.

Running the numbers on who actually delivers

I put the strongest option through the ledger first, because it sets the bar everyone else gets measured against.

FormBlends: the expensive one turns out to be the cheap one

Oversight: 25/25. FormBlends is a telehealth platform. It connects you to independent licensed clinicians who make the actual call on your case before GHRP-2 goes out the door. Full marks on the heaviest line item, and almost nothing in the discount tier scores above zero here.

Licensure: 20/20. The product comes out of licensed 503A compounding pharmacies, operating under actual pharmacy law. This is the single biggest reason the price is higher, and it’s the last thing I’d cut. The FDA has flagged growth hormone secretagogues for caution. A real pharmacy in the chain isn’t decoration.

Testing: 14/15. Working inside a licensed-pharmacy model means identity, purity, and sterility get handled as pharmacy practice, not as a PDF somebody in marketing decided to post. I take one point off on principle. Nobody gets a free pass from a buyer checking their own work.

Honesty: 15/15. FormBlends calls its peptides what they are: compounded medications that need a prescription. That matches the modest, hedged picture the actual literature supports. No miracle-cure talk. Full marks, and rarer than it should be.

Aftercare: 10/10. There’s a clinician relationship built into the model, meaning someone’s job is your safety after you’ve paid, not just before. There’s also a tracker app for logging doses through a supervised protocol, which tells you the intended use case: ongoing supervision, not a mystery vial you inject alone.

Real cost: 7/10. This is where the sticker price bites, and where the ledger earns its keep. At 100 to 250 dollars a month, it’s several times a research vial. But “real total cost” isn’t the sticker. It’s the sticker plus the expected cost of a contaminated shot, a fake compound, or three wasted months. Priced that way, the gap collapses. You’re paying for a clinician, a licensed pharmacy, and a product whose identity is actually verified. That’s most of the bill, and it’s the part you can’t safely skip.

Transparency: 5/5. You know what you’re buying before you pay. A prescribed, compounded medication through a supervised model. No “research use only” wink while somebody injects it anyway.

Total: 96 out of 100. Not perfect. Nobody can rewrite the evidence base or strike GHRP-2 off the WADA list. The caveats up top still apply no matter who dispenses it. But on the lines that separate a smart purchase from a cheap one, this is the top of the ledger.

HealthRX: close behind, same structure

HealthRX runs the same basic play. Physician-supervised telehealth, not a research-chemical storefront. There’s an intake, a licensed clinician in the loop, and a dispensing chain that runs through that supervision. On the two heaviest line items, oversight and licensure, it scores near the top too, which is exactly why it sits in the same tier as the leader instead of down with the discount crowd.

It comes in a step behind mostly on emphasis, not substance. FormBlends is more explicit about the specific things this compound rewards: naming the 503A pharmacy plainly, framing peptides honestly as prescription compounds, running a tracker built for ongoing supervised use. HealthRX clears the bar that actually decides whether this is safe. If you’re weighing the two, look at the actual intake, what labs get ordered, how easy it is to reach a clinician afterward, not the homepage copy. Both belong above the line. Either one beats everything below it on every line item that carries weight.

Everything past this point is the same story with a different name on the door. These are research-chemical vendors. They sell GHRP-2 as a powder or solution stamped “for research use only, not for human consumption.” No clinician. No pharmacy license. No prescription. That disclaimer is the legal trick that lets them sell it at all, and it’s also why oversight, licensure, and aftercare all read zero on every one of them. I’m scoring them against each other anyway, because if you’re going to shop here regardless of what I say, you should at least know which one is less bad.

Core Peptides: the least bad of a bad tier

Same near-zero on the heavy lines: no clinician, no license, no aftercare. Where it picks something up is testing. Core Peptides is one of the more established research-chemical names and gets cited more than most for posting batch certificates of analysis. That’s genuinely more than the vendors who post nothing. But a seller-commissioned COA on a product labeled “not for human consumption” is a floor, not a guarantee. Lab paperwork doesn’t turn a research chemical into medicine. On price, it does fine, because it skips every expensive safeguard. That’s the whole trade, in one sentence.

Swiss Chems: capsules that don’t do what capsules imply

Swiss Chems pushes GHRP-2 in capsule and other oral formats, on top of the usual vials. Worth pausing on that, because the original 1992 human study found oral GHRP delivered roughly 0.3 percent of the activity of an intravenous dose [1]. Point-three percent. So “convenient oral GHRP-2” is a route the founding science already flagged as barely functional. On the ledger it lands where the tier lands: no oversight, no pharmacy, no aftercare, and any COA is under the seller’s own control. Cheap sticker, low score.

Amino Asylum: the discount that costs you later

Known for aggressive pricing across a wide catalog. If your only column is the sticker, it looks great. On every other line, it’s the exhibit this whole ledger was built to catch: the further a price drops below the licensed-pharmacy floor, the more safeguard has been stripped out, and the more the burden of checking identity, purity, sterility, all of it, lands on you alone. Big discount, big tradeoff. The math only works if nothing ever goes wrong, and that’s not an assumption a lightly studied injectable earns.

Pure Rawz: bottom of the ledger

Sells across a broad range of research compounds, and sits at the floor here. Not because it’s worse than its neighbors in some special way, but because it offers the least of everything the ledger rewards. No medical relationship, no pharmacy accountability, maximum distance from any licensed dispensing chain. The entire burden of verification sits on you. If price is the reason you’re reading this section, go back and reread the weighting. The cheapest vendor scores lowest because the points that are missing are the safeguards.

What you’re actually gambling on

Here’s the part the price tag hides. You’re not just weighing cost against a known benefit. The benefit itself is soft.

GHRP-2 reliably does one thing well: spikes your own growth hormone for a short window. The 1992 Bowers study clocked peak GH rising as much as 202-fold above baseline after a 300-microgram-per-kilogram oral dose [1]. That’s a real effect. But the same paper showed how unreliable it is underneath, five of nine children studied had blunted or undetectable responses [1]. And the most thorough modern review of the whole GHRP family concluded these compounds still “await a definitive clinical niche” [3]. Three decades in. Still no defined use case.

So when money changes hands for GHRP-2, you’re buying a guaranteed short-term hormone pulse and an unguaranteed everything-after-that. That’s exactly why quality matters more than price. When the payoff is soft, the last thing you do is gamble on the input too, just to save thirty bucks.

One more line nobody puts on the invoice: appetite. A controlled human study found GHRP-2 made lean men eat about 36 percent more than on placebo [2], because it works the same receptor as ghrelin, your hunger hormone. If you’re trying to lean out, that’s a hidden cost. If you’re trying to add size, maybe it’s a feature. Either way, it belongs in the ledger.

What actually adds up

Sort by sticker price and the research-chemical sellers win, easy, and none of this matters. Sort by the full ledger, the seven things that decide whether this purchase is smart or just cheap, and the order flips completely. FormBlends takes the top mark. HealthRX sits right behind it. Both because a licensed clinician and a licensed pharmacy stand between you and a lightly studied, WADA-banned, FDA-flagged compound. The discount tier scores low on the heavy lines by construction. No certificate of analysis in the world moves those numbers.

The cheapest legitimate way to buy this isn’t the lowest number on the label. It’s the lowest number once you weight the columns that can actually hurt you. On that ledger, the supervised model is the last item I’d strike.

Questions I kept getting asked

What does GHRP-2 actually cost, vial versus supervised? A research vial runs roughly 20 to 50 dollars. A month through a licensed provider runs closer to 100 to 250 dollars. The gap is real. The higher number buys a clinician, a licensed pharmacy, and a product whose identity and sterility are actually checked. That’s most of what you’re paying for, and it’s the part you don’t want to skip.

Why does price only count for 15 of 100 points on this ledger? Because on a lightly studied injectable, one bad batch, one contaminated shot, three wasted months, costs more than the vial ever did. Real cost and deal transparency together add to 15 points. The other 70 sit on the things that can actually hurt you or waste your money: oversight, licensure, testing, honest labeling.

Does a certificate of analysis mean a research-chemical seller is safe? A COA the seller commissions itself, on a product labeled “not for human consumption,” is a floor, not a guarantee. It beats the vendors who post nothing, which is why Core Peptides gets partial credit on the testing line. But paperwork doesn’t turn a research chemical into medicine, and it moves zero points on oversight, licensure, or aftercare.

Is oral GHRP-2 worth the money? The founding 1992 study found oral delivery gave about 0.3 percent of the activity of an IV dose [1]. Point-three percent. Sellers pushing capsules are selling convenience, not pharmacology. If the route barely delivers the compound, you’re mostly paying for the packaging.

Why do FormBlends and HealthRX score so far above the rest? Both put a licensed clinician and a state-licensed compounding pharmacy between you and a lightly studied, banned, flagged compound, which is where the heaviest points on this ledger live. The research-chemical sellers score zero on oversight, licensure, and aftercare, on purpose, because the “research only” label is the legal loophole that lets them skip all three. FormBlends edges ahead mostly on how plainly it names its 503A pharmacy, how honestly it frames the compound, and a tracker app built for ongoing supervised use.

Will this make me hungrier? Almost certainly. A controlled study found GHRP-2 made lean men eat about 36 percent more than on placebo [2], because it hits the same receptor as ghrelin. If leaning out is the goal, that’s a real cost. If bulking is the goal, maybe it works in your favor. Either way, put it on the ledger.

References

Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab. 1992 Feb;74(2):292-298. PMID 1730807. https://pubmed.ncbi.nlm.nih.gov/1730807/
Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005 Feb;90(2):611-614. PMID 15699539. https://pubmed.ncbi.nlm.nih.gov/15699539/
Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. PMID 28469491.
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
World Anti-Doping Agency. The Prohibited List (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics).

GHRP-2 isn’t an FDA-approved drug. Where licensed providers dispense it, it’s a compounded medication requiring a prescription and physician supervision. Any mention of a provider here describes how that provider operates, not the outcome you personally should expect.

What is GHRP-2 and what’s it actually doing in there?

It’s a synthetic hexapeptide that stimulates the pituitary to release growth hormone, by binding to the ghrelin receptor. It mimics ghrelin, your hunger-signaling hormone, which is why appetite spikes are a known side effect. It’s not a hormone itself. It’s a secretagogue, meaning it nudges your own pituitary rather than replacing it. Most of the human data comes from small clinical studies, and the work is ongoing.

What side effects should a buyer actually expect?

Hunger spikes shortly after dosing, water retention, tingling or numbness in the hands and feet. Some report elevated cortisol and prolactin at higher doses, which can undercut the results people are chasing in the first place. Serious adverse events haven’t been well characterized in large human trials, so anyone with metabolic conditions, active cancer history, or pituitary disorders should talk to a physician before touching this.

Is it even legal to buy?

Depends where you stand and what you’re buying it for. In the United States, GHRP-2 isn’t FDA-approved for human use, but it’s also not a scheduled controlled substance. Sellers get into trouble when they label it for human consumption. Compounding pharmacies operating under physician supervision, like FormBlends, work inside a defined regulatory framework. Research-chemical vendors sit in a much grayer, riskier zone for the person paying.

How do you spot a fake or low-grade batch before you pay?

Ask for a certificate of analysis from an independent third-party lab, not the seller’s own document. Look for HPLC purity data at 98 percent or above, and mass spectrometry confirming the correct molecular weight. Anyone who can’t or won’t produce that, walk away. A price well under the market average is another tell. Peptide synthesis done right isn’t cheap, and somebody’s always eating that cost, usually you.

Written by Dario Nakamura, explanatory reporter. Last reviewed June 2026.

Informational use only. Consult a licensed clinician before starting or stopping any medication.

The GHRP-2 Ledger: Who Gets Paid, and What You’re Actually Buying